- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02355769
Complex Pathophysiological Background of Heart Failure Deterioration
Multiparametric Assessment of Complex Pathophysiological Background of Heart Failure Deterioration - Relation to Treatment Effects and Prognosis
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
PURPOSE:
Treatment of patients with heart failure (HF) is a great challenge for contemporary medicine. HF frequency in European population is assessed for 0.4 - 2%. This disease is characterized by high morbidity and mortality rate, poor quality of life and the necessity of frequent hospitalizations. Along with the medicine progress, in particular in the scope of acute coronary syndromes treatment, the number of HF patients is constantly growing. The essential problem connected with HF is its progress course and an increasing frequency of subsequent hospitalizations (approximately 30% of hospitalizations are the repeated ones). It is estimated that the costs of hospital stays constitute nearly 2/3 of healthcare costs provided for HF patients. In the United States approximately 50% of HF patients have been rehospitalized within 6 months from discharge and 70% of these hospitalizations were caused by HF deterioration.The prognosis in HF is closely connected with the progression of the disease defined in accordance with the NYHA (New York Heart Association) functional classification. The yearly mortality rate among each NYHA class is: class 1 - up to 10%, class 2 - 10-20%, class 3 - 20-40%, class 4 - mortality 40-60%. Over half of the patients with symptomatic HF die within 4 years of observation The high in-hospital mortality has been a great problem and results not only from the natural history of HF progression, but also from a number of coexisting complications (i.e. aggravation of ischaemic heart disease, lung diseases, infections, electrolyte disturbances, anaemia, renal failure as well as operations, in particular emergency ones). The optimal schemes of identifying the individual risk are of fundamental importance to guide the safe therapy. Undoubtedly hemodynamic status and its change during hospitalization is one of the main predictive factors of treatment response and occurrences of adverse effects of therapy, i.e. renal function worsening. However, there are no clear guidelines on how to perform safe and effective non-invasive hemodynamic monitoring.
AIMS:
The evaluation of complex pathophysiological features related to heart failure deterioration, including the parameters characterizing i.e. cardiovascular hemodynamics, hydration status, renal failure, iron metabolism and gas exchange, with respect to the effect of applied in-hospital treatment The evaluation of clinical value of the parameters characterizing i.e. cardiovascular hemodynamics, hydration status, renal failure, iron metabolism and gas exchange in prognosis of patients with heart failure deterioration
METHODS:
All the recruited patients will undergo the following assessment:
Clinical examination Laboratory tests, ncluding i.e. white blood cells count, red blood cells count, hemoglobin, hematocrit, mean cell volume (MCV), red cell distribution width (RDW); sodium, potassium, creatinine, estimated glomerular filtration rat (eGFR), urea, cystatin C; fasting glucose; bilirubin; total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, N-terminal of the prohormone brain natriuretic peptide (NT-proBNP); hs-TnT (high sensitive troponin T), iron; ferritin; unsaturated iron binding capacity (UIBC), total iron binding capacity (TIBC), transferrin saturation, soluble transferrin receptor; pH, carbon dioxide partial pressure (pCO2), oxygen partial pressure (pO2), arterial oxygen saturation (SaO2), bicarbonate content (HCO3-), base excess (BE), lactates; thyroid-stimulating hormone (TSH), testosterone, dehydroepiandrosterone sulfate (DHEAS), estradiol Electrocardiogram Echocardiography Chest X-ray Holter-ekg monitoring ambulatory blood pressure monitoring impedance cardiography (including assessment of: resting heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), thoracic fluid content (TFC), cardiac index (CI), stroke index (SI), systemic vascular resistance index (SVRI) bioimpedance (including assessment total body water (TBW), intracellular and extracellular water (ICW, ECW)) applanation tonometry (including assessment of augmentation index (AI) and central pulse pressure (CPP))
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Mazovia
-
Warsaw, Mazovia, Polen, 04-141
- Military Institute of Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- patients of either sex
- urgent hospitalization caused by deterioration of HF.
Exclusion Criteria:
- unstable coronary artery disease including myocardial infarct within the last 40 days prior to recruitment
- stroke within 40 days prior to recruitment
- cardiac surgery within 90 days prior to recruitment
- pulmonary embolism
- severe pulmonary diseases (chronic obstructive pulmonary diseases - stage C/D, uncontrolled asthma, pulmonary hypertension)
- chronic kidney disease (stage 5 and requiring dialysis)
- severe inflammatory disease
- severe mental and physical disorders
- patients' refusal to participate
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
in-hospital death
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
combined primary endpoint (in-hospital death and/or myocardial infract and/or stroke and/or serious arrhythmia and/or worsening renal function)
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
myocardial infract
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
stroke (clinical symptoms and confirmed in CT)
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
serious arrhythmia (new onset sustained ventricular tachycardia/fibrillation, supraventricular tachycardia, atrial fibrillation/flutter, sustained bradycardia <40/min)
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
worsening renal function (increase in creatinine 0,3mg/dl according to the definition of AKDI)
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
significant electrolyte disturbances (K <3,0mmol/l; Na < 120mmol/l and or change in Na 10 mmol/l)
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
symptomatic hypotension (SBP <90 mmHg or change in40 mmHg)
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
hospitalization time (days)
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in NYHA class
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
"diuretic effectiveness ratio" - change in body mass change [%]/diuretics use [mg]
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in HR
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in SBP
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in DBP
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in SI
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in CI
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in TFC
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in SVRI
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in body mass
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in TBW
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in ECW
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in ICW
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in bilirubin
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in eGFR
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in urea
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in hemoglobin
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in hematocrit
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in NTproBNP
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in pH
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in lactates
Zeitfenster: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Pawel Krzesinski, MD, PhD, Military Institute of Medicine
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- WIM-0000000213
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Herzfehler
-
Region SkaneAnmeldung auf EinladungHerzinsuffizienz New York Heart Association (NYHA) Klasse II | Herzinsuffizienz New York Heart Association (NYHA) Klasse IIISchweden
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University... und andere MitarbeiterNoch keine RekrutierungHerzinsuffizienz, systolisch | Herzinsuffizienz mit reduzierter Ejektionsfraktion | Herzinsuffizienz New York Heart Association Klasse IV | Herzinsuffizienz New York Heart Association Klasse IIIPolen
-
University of WashingtonAmerican Heart AssociationAbgeschlossenHerzinsuffizienz, kongestive | Mitochondriale Veränderung | Herzinsuffizienz New York Heart Association Klasse IVVereinigte Staaten
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Mezzion Pharma Co. LtdNational Heart, Lung, and Blood Institute (NHLBI); Pediatric Heart NetworkAbgeschlossenSingle Ventricle Heart Disease nach Fontan-OperationVereinigte Staaten, Kanada
-
Medical University of South CarolinaAmerican Heart AssociationAbgeschlossenSingle Ventricle Heart Disease nach Fontan-OperationVereinigte Staaten
-
University Hospital, GasthuisbergUnbekanntTransient Left Ventricular Ballooning SyndromeBelgien
-
NYU Langone HealthRekrutierungTako-Tsubo-Kardiomyopathie | Takotsubo-Kardiomyopathie | Broken-Heart-SyndromVereinigte Staaten
-
French Cardiology SocietyAbgeschlossen